AR050635A1 - Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo, procedimientos para su preparacion su uso como medicamento o agente de diagnostico, y medicamento que las comprende - Google Patents

Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo, procedimientos para su preparacion su uso como medicamento o agente de diagnostico, y medicamento que las comprende

Info

Publication number
AR050635A1
AR050635A1 ARP050103754A ARP050103754A AR050635A1 AR 050635 A1 AR050635 A1 AR 050635A1 AR P050103754 A ARP050103754 A AR P050103754A AR P050103754 A ARP050103754 A AR P050103754A AR 050635 A1 AR050635 A1 AR 050635A1
Authority
AR
Argentina
Prior art keywords
atoms
alkyl
independently
so2ch3
alkoxy
Prior art date
Application number
ARP050103754A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR050635A1 publication Critical patent/AR050635A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
    • C07C323/02—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/07—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo de la formula (1), adecuadas, por ejemplo, como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto, y para el tratamiento de la angina de pecho. También inhiben preventivamente las propiedades patofisiologicas asociadas con el desarrollo e lesiones inducidas por isquemia, especialmente en el desencadenamiento de arritmias cardíaca inducidas por isquemia. Reivindicacion 1:Una pentafluorosulfanilbenzoilguanidina de la formula (1) en la que los significados son: R1 y R1' independientemente uno del otro, H, alquilo que tiene 1, 2, 3 o 4 átomos de C, alcoxi que tiene 1, 2, 3 o 4 de C, F, Cl, Br, I, -CN, NR6R7, -O-(CH2)b-(CF2)c-CF3 o -(SOd)e-(CH2)g-CF3; R6 y R7 independientemente uno del otro, H, alquilo que tiene 1, 2, 3 o 4 átomos de C o -CH2-CF3; d es 0, 1 o 2; b, c, e, f y g independientemente unos de otros, 0 o 1; R2 y R2' independientemente uno del otro H, F, Cl, Br, I, -CN, -SO2CH3, alcoxi que tiene 1, 2, 3 o 4 átomos de C, NR6R7, -O-(CH2)b-(CF2)c-CF3, -(SOh)k-(CH2)l-(CF2)m-CF3, alquilo que tiene 1, 2, 3, 4, 5 o 6 átomos de C, cicloalquilo que tiene 3, 4, 5, 6, 7 u 8 átomos de C, en los que 1, 2, 3 o 4 átomos de H pueden estar reemplazados con átomos de F, -(CH2)n- fenilo que no está sustituido o está sustituido con 1, 2 o 3 radicales seleccionados entre el grupo que consiste en F, Cl, Br, I -Oo-(CH2)p-CF3, alcoxi que tiene 1, 2, 3 o 4 átomos de C, alquilo que tiene 1, 2, 3 o 4 átomos de C y -SO2CH3, o -(CH2)q-heteroarilo que no está sustituido o está sustituido con 1, 2 o 3 radicales seleccionados entre el grupo que consiste en F, Cl, Br, I, -Or- (CH2)s-CF3, alcoxi que tiene 1, 2, 3 o 4 átomos de C, alquilo que tiene 1, 2, 3 o 4 átomos de C y -SO2CH3; R6 y R7 independientemente uno del otro, H, alquilo que tiene 1, 2, 3 o 4 átomos de C o -CH2-CF3; b y c independientemente uno del otro, 0 o 1; h 0, 1 o 2; k 0 o 1; l 0, 1, 2, 3 o 4; m y o independientemente uno del otro, 0 o 1; p 0, 1, 2 o 3; n 0, 1, 2, 3 o 4; r 0 o 1; s 0, 1, 2, o 3; q 0, 1, 2, 3 o 4; R3 H, F, Cl, Br, I, -CN, -SO2CH3, alquilo que tiene 1, 2, 3, 4, 5 o 6 átomos de C, alcoxi que tiene 1, 2, 3 o 4 átomos de C o -Ot-(CH2)u-CF3; t 0 o 1; u 0, 1, 2 o 3; R4 H, F, Cl, Br, I, -CN, -SO2CH3, NR6R7, -(SOv)w-(CH2)x-(CF2)y-CF3, -O-(CH2)aa-(CF2)bb-CF3, alquilo que tiene 1, 2, 3, 4, 5 o 6 átomos de C, alcoxi que tiene 1, 2, 3 o 4 átomos de C o cicloalquilo que tiene 3, 4, 5, 6, 7 u 8 átomos de C, en los que 1, 2, 3 o 4 átomos de H pueden estar reemplazados con átomos de F; R6 y R7 independientemente uno del otro, H, alquilo que tiene 1, 2, 3 o 4 átomos de C o -CH2-CF3; v 0, 1 o 2; x 0, 1, 2, 3 o 4; w, y, aa y bb independientemente unos de otros, 0 o 1; o R4 -(CH2)cc-fenilo, que no está sustituido o está sustituido con 1, 2 o 3 radicales seleccionados entre el grupo que consiste en F, Cl, Br, I, -Odd-(CH2)ee-CF3, alcoxi que tiene 1, 2, 3 o 4 átomos de C, alquilo que tiene 1, 2, 3 o 4 átomos de C y -SO2CH3; dd 0 o 1; ee 0, 1, 2, o 3; cc 0, 1, 2, 3 o 4; o R4 -(CH2)ff-heteroarilo, que no está sustituido o está sustituido con 1, 2, o 3 radicales seleccionados entre el grupo que consiste en F, Cl, Br, I, -Ogg-(CH2)hh-CF3, alcoxi que tiene 1, 2, 3 o 4 átomos de C, alquilo que tiene 1, 2, 3 o 4 átomos de C y -SO2CH3; gg 0 o 1; hh 0, 1, 2 o 3; ff 0, 1, 2,3 o 4; R5 F, Cl, Br, I, CF3, -SO2CH3 o -S(O)OCH3; X un enlace directo, O, NR8, S(O)kk; R8 H, alquilo que tiene 1, 2, 3 o 4 átomos de C, -(CH2)mm-CF3 o -SO2CH3, kk 0, 1 o 2; mm 0, 1, 2 o 3; en los que -O-(CH2)b-(CF2)c-CF3 en las definiciones de R1 y R1', y R2 y R2' se puede seleccionar independientemente uno de otro, en los que NR6R7 en las definiciones de R1 y R1'; R2 y R2' y R4 se puede seleccionar independientemente uno del otro, y sus sales farmacéuticamente aceptables.
ARP050103754A 2004-09-11 2005-09-08 Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo, procedimientos para su preparacion su uso como medicamento o agente de diagnostico, y medicamento que las comprende AR050635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004043938A DE102004043938A1 (de) 2004-09-11 2004-09-11 Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR050635A1 true AR050635A1 (es) 2006-11-08

Family

ID=35335730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103754A AR050635A1 (es) 2004-09-11 2005-09-08 Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo, procedimientos para su preparacion su uso como medicamento o agente de diagnostico, y medicamento que las comprende

Country Status (17)

Country Link
US (1) US7446225B2 (es)
EP (1) EP1791813B1 (es)
JP (1) JP2008512410A (es)
KR (1) KR20070053747A (es)
CN (1) CN101014566A (es)
AR (1) AR050635A1 (es)
AT (1) ATE430130T1 (es)
AU (1) AU2005281929A1 (es)
BR (1) BRPI0515148A (es)
CA (1) CA2580132A1 (es)
DE (2) DE102004043938A1 (es)
IL (1) IL181556A0 (es)
MX (1) MX2007001921A (es)
PE (1) PE20060597A1 (es)
TW (1) TW200621687A (es)
UY (1) UY29113A1 (es)
WO (1) WO2006027130A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
WO2012111839A1 (en) 2011-02-15 2012-08-23 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK0723956T3 (da) * 1995-01-30 2000-04-17 Hoechst Ag Basisk substituerede benzoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemiddel eller diagnos
US6057322A (en) * 1995-01-30 2000-05-02 Hoechst Aktiengesellschaft Basically-substituted benzoylguanidines, a process for preparing them, their use as a medicament or diagnostic agent, and a medicament containing them
US7375138B2 (en) * 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
DE10222192A1 (de) * 2002-05-18 2003-11-27 Aventis Pharma Gmbh Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6878748B2 (en) * 2002-06-13 2005-04-12 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
DE10226462A1 (de) * 2002-06-13 2003-12-24 Aventis Pharma Gmbh Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US7381841B2 (en) * 2003-08-22 2008-06-03 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US20050124666A1 (en) * 2003-11-13 2005-06-09 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same

Also Published As

Publication number Publication date
PE20060597A1 (es) 2006-08-03
US20070259963A1 (en) 2007-11-08
WO2006027130A1 (de) 2006-03-16
UY29113A1 (es) 2006-04-28
DE102004043938A1 (de) 2006-03-30
IL181556A0 (en) 2007-07-04
CN101014566A (zh) 2007-08-08
TW200621687A (en) 2006-07-01
DE502005007202D1 (de) 2009-06-10
US7446225B2 (en) 2008-11-04
ATE430130T1 (de) 2009-05-15
EP1791813A1 (de) 2007-06-06
JP2008512410A (ja) 2008-04-24
EP1791813B1 (de) 2009-04-29
MX2007001921A (es) 2007-04-23
BRPI0515148A (pt) 2008-07-08
CA2580132A1 (en) 2006-03-16
KR20070053747A (ko) 2007-05-25
AU2005281929A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
UY27891A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
GT200000216A (es) Oxazolidinonas sustituidas y su uso.
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
PA8558001A1 (es) Derivados de isonicotin y nicotinamida de benzotiazoles
UY28132A1 (es) Derivados de pirrolopirimidina
BR112019020175A2 (pt) Derivados de indolina substituídos como inibidores da replicação viral da dengue
GT200000161A (es) Compuestos para el tratamiento de la isquemia.
AR017796A1 (es) DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD.
PE20070210A1 (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c
PA8547701A1 (es) Nucleosidos 4 substituidos.
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
AR040201A1 (es) Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
BRPI0410913A (pt) benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
ECSP088084A (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
AR062398A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
UY27835A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
AR050635A1 (es) Benzoilguanidinas sustituidas con pentafluorosulfanilfenilo, procedimientos para su preparacion su uso como medicamento o agente de diagnostico, y medicamento que las comprende
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
UY28959A1 (es) Compuestos basados en bispidinas, 3,7-diazabiciclo (3,3,1)nonanos, particularmente oxabispidinas, sus sales y solvatos, composiciones conteniéndolos y procedimientos de preparación.

Legal Events

Date Code Title Description
FB Suspension of granting procedure